HRP20021039B1 - Ciklopentanoindoli, pripravci koji sadržavaju takve spojeve i metode liječenja - Google Patents

Ciklopentanoindoli, pripravci koji sadržavaju takve spojeve i metode liječenja

Info

Publication number
HRP20021039B1
HRP20021039B1 HR20021039A HRP20021039A HRP20021039B1 HR P20021039 B1 HRP20021039 B1 HR P20021039B1 HR 20021039 A HR20021039 A HR 20021039A HR P20021039 A HRP20021039 A HR P20021039A HR P20021039 B1 HRP20021039 B1 HR P20021039B1
Authority
HR
Croatia
Prior art keywords
optionally substituted
halogen
independently selected
ora
heteroaryl
Prior art date
Application number
HR20021039A
Other languages
English (en)
Croatian (hr)
Inventor
Labelle Marc
Sturino Claudio
Roy Bruno
Berthelette Carl
Boyd Michael
Lachance Nicolas
Scheigetz John
Original Assignee
Merck Frosst Canada & Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada & Co. filed Critical Merck Frosst Canada & Co.
Publication of HRP20021039A2 publication Critical patent/HRP20021039A2/hr
Publication of HRP20021039B1 publication Critical patent/HRP20021039B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. Transmission Power Control [TPC] or power classes
    • H04W52/04—Transmission power control [TPC]
    • H04W52/38—TPC being performed in particular situations
    • H04W52/46—TPC being performed in particular situations in multi-hop networks, e.g. wireless relay networks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04B—TRANSMISSION
    • H04B17/00—Monitoring; Testing
    • H04B17/30—Monitoring; Testing of propagation channels
    • H04B17/309—Measuring or estimating channel quality parameters
    • H04B17/318—Received signal strength
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W48/00—Access restriction; Network selection; Access point selection
    • H04W48/02—Access restriction performed under specific conditions
    • H04W48/04—Access restriction performed under specific conditions based on user or terminal location or mobility data, e.g. moving direction, speed
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. Transmission Power Control [TPC] or power classes
    • H04W52/04—Transmission power control [TPC]
    • H04W52/06—TPC algorithms
    • H04W52/14—Separate analysis of uplink or downlink
    • H04W52/146—Uplink power control
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. Transmission Power Control [TPC] or power classes
    • H04W52/04—Transmission power control [TPC]
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. Transmission Power Control [TPC] or power classes
    • H04W52/04—Transmission power control [TPC]
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/28—TPC being performed according to specific parameters using user profile, e.g. mobile speed, priority or network state, e.g. standby, idle or non-transmission
    • H04W52/288—TPC being performed according to specific parameters using user profile, e.g. mobile speed, priority or network state, e.g. standby, idle or non-transmission taking into account the usage mode, e.g. hands-free, data transmission or telephone
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W48/00—Access restriction; Network selection; Access point selection
    • H04W48/20—Selecting an access point
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. Transmission Power Control [TPC] or power classes
    • H04W52/04—Transmission power control [TPC]
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. Transmission Power Control [TPC] or power classes
    • H04W52/04—Transmission power control [TPC]
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
    • H04W52/245—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters taking into account received signal strength
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. Transmission Power Control [TPC] or power classes
    • H04W52/04—Transmission power control [TPC]
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
    • H04W52/247—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters where the output power of a terminal is based on a path parameter sent by another terminal

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Quality & Reliability (AREA)
  • Electromagnetism (AREA)
  • Physics & Mathematics (AREA)
  • Computer Security & Cryptography (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Steroid Compounds (AREA)
  • Materials For Photolithography (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
HR20021039A 2000-07-25 2001-07-23 Ciklopentanoindoli, pripravci koji sadržavaju takve spojeve i metode liječenja HRP20021039B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22068300P 2000-07-25 2000-07-25
PCT/CA2001/001069 WO2002008186A2 (en) 2000-07-25 2001-07-23 Cyclopentanoindoles, compositions containing such compounds and methods of treatment

Publications (2)

Publication Number Publication Date
HRP20021039A2 HRP20021039A2 (en) 2004-10-31
HRP20021039B1 true HRP20021039B1 (hr) 2011-03-31

Family

ID=22824535

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20021039A HRP20021039B1 (hr) 2000-07-25 2001-07-23 Ciklopentanoindoli, pripravci koji sadržavaju takve spojeve i metode liječenja

Country Status (33)

Country Link
US (1) US6410583B1 (cs)
EP (1) EP1305286B1 (cs)
JP (1) JP4119745B2 (cs)
KR (1) KR100746814B1 (cs)
CN (1) CN1214007C (cs)
AT (1) ATE284388T1 (cs)
AU (2) AU2001277430B2 (cs)
BG (1) BG66084B1 (cs)
BR (1) BR0112756A (cs)
CA (1) CA2416867C (cs)
CZ (1) CZ2003236A3 (cs)
DE (1) DE60107687T2 (cs)
DK (1) DK1305286T3 (cs)
DZ (1) DZ3402A1 (cs)
EA (1) EA006765B1 (cs)
EC (1) ECSP034428A (cs)
EE (1) EE05287B1 (cs)
ES (1) ES2231526T3 (cs)
GE (1) GEP20053595B (cs)
HR (1) HRP20021039B1 (cs)
HU (1) HUP0301745A3 (cs)
IL (2) IL153406A0 (cs)
IS (1) IS2170B (cs)
MX (1) MXPA03000710A (cs)
NO (1) NO325011B1 (cs)
NZ (1) NZ523106A (cs)
PL (1) PL207342B1 (cs)
PT (1) PT1305286E (cs)
RS (1) RS50491B (cs)
SK (1) SK287507B6 (cs)
UA (1) UA73787C2 (cs)
WO (1) WO2002008186A2 (cs)
ZA (1) ZA200300554B (cs)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
DK1105096T3 (da) 1998-08-19 2004-03-08 Skyepharma Canada Inc Injicerbare vandige propofoldispersioner
US7273883B2 (en) * 2000-09-14 2007-09-25 Allergan, Inc. Prostaglandin EP4 antagonist
US7217725B2 (en) * 2000-09-14 2007-05-15 Allergan, Inc. Prostaglandin D2 antagonist
AR031195A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de 1,2,3,4,8,9,10,10a-octahidro-7bh-ciclopenta (b) (1,4) diazepino (6,7,1) diazepino (6,7,1-hi) indol
US6784172B2 (en) 2000-11-03 2004-08-31 Wyeth Processes for preparation of cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AR031200A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados
AU2002239463A1 (en) * 2000-11-03 2002-06-03 Wyeth Cyclopenta(b)(1,4) diazepino(6,7,1-hi)indoles as 5ht2c antagonists
US6858604B2 (en) 2000-11-03 2005-02-22 Wyeth Cyclohepta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
US6777407B2 (en) 2000-11-03 2004-08-17 Wyeth Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
US7141563B2 (en) 2000-11-03 2006-11-28 Wyeth Process for the preparation of 1, 2, 3, 4, 8, 9, 10, 10a-octahydro-7bH-cyclopenta[b] [1, 4]diazepino[6, 7, 1-hi] indole derivatives
AR038136A1 (es) * 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200400963A (en) 2002-05-21 2004-01-16 Wyeth Corp R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease
TW200400818A (en) 2002-05-21 2004-01-16 Wyeth Corp Method for the use of pyranoindole derivatives to treat infection with hepatitis C virus
AR041089A1 (es) * 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
CN1791577A (zh) * 2003-05-20 2006-06-21 麦克弗罗斯特加拿大有限公司 氟－甲基磺酰取代的环烷并吲哚和它们作为前列腺素d2拮抗剂的用途
JP2006527205A (ja) * 2003-06-12 2006-11-30 メルク フロスト カナダ リミテツド Ｄｐ受容体拮抗物質としてのシクロアルカンピロロピリジン
ATE464048T1 (de) * 2003-08-07 2010-04-15 Merck Sharp & Dohme Behandlung von alzheimer-krankheit und verwandten zuständen
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
CA2573673A1 (en) 2004-07-16 2006-01-26 Proteosys Ag Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents
HN2005000795A (es) * 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
CA2603757A1 (en) * 2005-04-13 2006-10-26 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
US7902177B2 (en) 2005-05-02 2011-03-08 Wandzel Richard A Treatment of congestion using steroids and adrenergics
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
US20100260841A1 (en) * 2007-02-08 2010-10-14 Paolini John F Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
DK2326621T3 (en) 2008-07-23 2016-09-12 Arena Pharm Inc Substituted 1,2,3,4-tetrahydrocyclopenta [b] indol-3-yl acetic acid derivatives suitable for the treatment of autoimmune and inflammatory disorders
BRPI0917923B1 (pt) 2008-08-27 2022-04-05 Arena Pharmaceuticals Inc Derivado de ácido tricíclico substituído, sua composição, seu uso e processo para preparar a referida composição
US8507473B2 (en) 2008-09-11 2013-08-13 Arena Pharmaceuticals, Inc. 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders
WO2010034110A1 (en) * 2008-09-25 2010-04-01 Merck Frosst Canada Ltd. Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
WO2010081825A2 (en) 2009-01-13 2010-07-22 Proteosys Ag Pirenzepine as an agent in cancer treatment
CN102741244A (zh) 2009-10-26 2012-10-17 拜耳作物科学公司 4-[[(6-氯吡啶-3-基)甲基](2,2-二氟乙基)氨基]呋喃-2(5h)-酮的新固体形式
EP2528894A1 (en) 2010-01-27 2012-12-05 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
WO2011109471A1 (en) 2010-03-03 2011-09-09 Arena Pharmaceuticals, Inc. Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
WO2014066568A1 (en) 2012-10-24 2014-05-01 Winthrop-University Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
US20180021302A1 (en) 2015-02-13 2018-01-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
IL285890B (en) 2015-06-22 2022-07-01 Arena Pharm Inc Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid
JP2020507611A (ja) 2017-02-16 2020-03-12 アリーナ ファーマシューティカルズ， インコーポレイテッド 原発性胆汁性胆管炎の治療のための化合物および方法
AU2018222747A1 (en) 2017-02-16 2019-09-05 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
EP3682250A4 (en) 2017-09-13 2021-03-03 Progenity, Inc. PRE-ECAMPSY BIOMARKERS AND ASSOCIATED SYSTEMS AND PROCESSES
US11279656B2 (en) 2017-10-27 2022-03-22 Applied Materials, Inc. Nanopowders, nanoceramic materials and methods of making and use thereof
MX2020013157A (es) 2018-06-06 2021-04-29 Arena Pharm Inc Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.
CN119751336A (zh) 2018-09-06 2025-04-04 艾尼纳制药公司 可用于治疗自身免疫性病症和炎性病症的化合物
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
CN115260173B (zh) * 2021-04-30 2024-08-30 厦门宝太生物科技股份有限公司 环戊烷并吲哚类支链酸衍生物及其制备方法和应用
CN116854622A (zh) * 2023-07-10 2023-10-10 青岛科技大学 一种多取代的2,4-二氢环戊二烯并[b]吲哚类化合物的合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535326A (en) * 1967-03-06 1970-10-20 Sumitomo Chemical Co Certain tetrahydro carboline derivatives
EP0234708A1 (en) * 1986-01-23 1987-09-02 Merck Frosst Canada Inc. Tetrahydrocarbazole 1-alkanoic acids
EP0468785A2 (en) * 1990-07-26 1992-01-29 Merck Frosst Canada Inc. (Quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787444A (fr) 1971-08-13 1973-02-12 Hoffmann La Roche Composes polycycliques
US4009181A (en) 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en) 1973-10-01 1977-11-08 American Home Products Corporation Carbazole acetic acid derivatives
US4808608A (en) 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
GB9101375D0 (en) 1991-01-22 1991-03-06 Erba Carlo Spa N-imidazolyl derivatives of substituted tetrahydrocarbazole and cyclohepht(b)indole
CZ285870B6 (cs) * 1995-06-21 1999-11-17 Shionogi & Co., Ltd. Bicyklické aminoderiváty a antagonist PGD2, který je obsahuje
ATE223911T1 (de) * 1996-12-13 2002-09-15 Shionogi & Co Benzothiophenecarboxamid-derivate und diese enthaltende pgd2 antagonisten
AU3955199A (en) * 1998-06-03 1999-12-20 Shionogi & Co., Ltd. Remedies for itching containing PGD2 antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535326A (en) * 1967-03-06 1970-10-20 Sumitomo Chemical Co Certain tetrahydro carboline derivatives
EP0234708A1 (en) * 1986-01-23 1987-09-02 Merck Frosst Canada Inc. Tetrahydrocarbazole 1-alkanoic acids
EP0468785A2 (en) * 1990-07-26 1992-01-29 Merck Frosst Canada Inc. (Quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes

Also Published As

Publication number Publication date
CZ2003236A3 (cs) 2003-05-14
JP2004504380A (ja) 2004-02-12
EP1305286B1 (en) 2004-12-08
NO325011B1 (no) 2008-01-14
EE200300033A (et) 2004-10-15
AU2001277430B2 (en) 2006-05-25
KR100746814B1 (ko) 2007-08-06
US6410583B1 (en) 2002-06-25
IL153406A (en) 2008-03-20
HUP0301745A3 (en) 2010-03-29
BG66084B1 (bg) 2011-03-31
SK287507B6 (sk) 2010-12-07
PL363168A1 (en) 2004-11-15
BG107438A (bg) 2003-09-30
PT1305286E (pt) 2005-04-29
AU7743001A (en) 2002-02-05
IS6655A (is) 2002-12-12
ES2231526T3 (es) 2005-05-16
GEP20053595B (en) 2005-08-10
DE60107687D1 (de) 2005-01-13
RS50491B (sr) 2010-03-02
NO20030374D0 (no) 2003-01-24
ATE284388T1 (de) 2004-12-15
IS2170B (is) 2006-11-15
HK1058934A1 (en) 2004-06-11
KR20030024810A (ko) 2003-03-26
UA73787C2 (en) 2005-09-15
CN1443165A (zh) 2003-09-17
EA200300171A1 (ru) 2003-06-26
JP4119745B2 (ja) 2008-07-16
WO2002008186A3 (en) 2002-03-21
ZA200300554B (en) 2004-04-23
YU97902A (sh) 2006-05-25
DZ3402A1 (fr) 2002-01-31
EP1305286A2 (en) 2003-05-02
HUP0301745A2 (hu) 2003-09-29
CN1214007C (zh) 2005-08-10
NO20030374L (no) 2003-01-24
MXPA03000710A (es) 2003-06-04
EA006765B1 (ru) 2006-04-28
NZ523106A (en) 2005-01-28
PL207342B1 (pl) 2010-12-31
CA2416867A1 (en) 2002-01-31
DK1305286T3 (da) 2005-03-14
ECSP034428A (es) 2003-03-10
DE60107687T2 (de) 2005-12-01
WO2002008186A2 (en) 2002-01-31
IL153406A0 (en) 2003-07-06
CA2416867C (en) 2008-03-25
BR0112756A (pt) 2003-06-24
EE05287B1 (et) 2010-04-15
HRP20021039A2 (en) 2004-10-31
SK932003A3 (en) 2003-06-03

Similar Documents

Publication Publication Date Title
HRP20021039B1 (hr) Ciklopentanoindoli, pripravci koji sadržavaju takve spojeve i metode liječenja
EE200200190A (et) Trifenüülalkeeni derivaadid ja nende kasutamine selektiivsete östrogeeniretseptorite modulaatoritena
DE69501947D1 (de) SUBSTITUIERTE AROMATISCHE VERBINDUNGEN ALS c. AMP PHOSPHODIESTERASE-UND TNF-HEMMER
YU68896A (sh) Jedinjenja hinolina i nihazolina od koristi u terapiji
CY1106497T1 (el) Νεες αρυλοξυ-αλκυλ-διαλκυλαμινες
YU165391A (sh) Derivati indola
YU48855B (sh) Heterociklična jedinjenja i njihovi derivati koji su modifikatori dejstva 5-hidroksi-triptamina i postupak njihovog dobijanja
HRP20040977B1 (hr) Derivati n-[fenil(piperidin-2-il)metil]benzamida,postupak njihovog pripravljanja i primjena istih u terapiji
CO5280046A1 (es) Agonistas alfa 7 y sus composiciones farmaceuticas
DK0673375T3 (da) Kondenserede benzoforbindelser
PT1140916E (pt) Acetais heteroarilo ciclicos
HRP20021023B1 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
EA200000792A3 (ru) Новые пиридиновые соединения, способ их получения и содержащие их фармацевтические композиции
HRP20070498T3 (en) Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP9900584A2 (hu) Új benzoil-guanidin-származékok, eljárás előállításukra és gyógyszerkészítmények előállításában való felhasználásuk
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
ES502264A0 (es) Procedimiento de preparacion de nuevos derivados de acido 4-hidroxi-3-quinolein-carboxilico,sustituidos en posicion 2
ATE135344T1 (de) Aromatische ester von phenylendialkanoaten als inhibitoren humaner neutrophiler elastase
CO4920251A1 (es) Compuestos hexahidro 1 h. -pirrolizina 7 a. -heterociclico- substituidos utiles en el control de la transmision sinaptica quimica
HRP20000878B1 (hr) Kemijska sinteza derivata morfolina
MEP12108A (en) Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them
MEP21808A (en) Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same
DK50089A (da) 2-oe(4-piperidinyl)methylaa-1,2,3,4-tetrahydroisoquinolin-derivater, fremgangsmaade til fremstilling af saadanne forbindelser og laegemiddel indeholdende disse
YU47605B (sh) Postupak za dobijanje supstituisanih derivata stirena
ATE365722T1 (de) 2,4,6-tris(4'aminobenzaldineopentylmalonat)-s- triazin, dieser enthaltenden sonnenschutzzusammensetzungen und dessen verwendungen

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20130716

Year of fee payment: 13

PBON Lapse due to non-payment of renewal fee

Effective date: 20140723